Two new rotavirus vaccines have recently been licensed in many countries. However, their effi cacy has only been shown against certain serotypes commonly circulating in Europe, North America, and Latin America, but thought to be globally important. To assess the potential impact of these vaccines in sub-Saharan Africa, where rotavirus mortality is high, knowledge of prevalent types is essential because an eff ective rotavirus vaccine is needed to protect against prevailing serotypes in the community. We did two systematic reviews and two meta-analyses of the most recent published data on the burden of rotavirus disease in children aged under 5 years and rotavirus serotypes circulating in countries in sub-Saharan Africa. Eligible studies were selected from PubMed/Medline, Cochrane Library, EmBase, LILACS, Academic Search Premier, Biological Abstracts, ISI Web of Science, and the African Index Medicus. Depending on the heterogeneity, DerSimonian-Laird random-eff ects or fi xed-eff ects models were used for meta-analyses. Geographical variability in rotavirus burden within countries in sub-Saharan Africa is substantial, and most countries lack information on rotavirus epidemiology. We estimated that annual mortality for this region was 243·3 (95% CI 187·6-301·7) deaths per 100 000 under 5 years (ie, a total of 300 000 children die of rotavirus infection in this region each year). The most common G type detected was G1 (34·9%), followed by G2 (9·1%), and G3 (8·6%). The most common P types detected were P[8] (35·5%) and P[6] (27·5%). Accurate information should be collected from surveillance based on standardised methods in these countries to obtain comparable data on the burden of disease and the circulating strains to assess the potential impact of vaccine introduction.
Introduction
Two large clinical trials, published in January, 2006, assessed the effi cacy and safety of two rotavirus vaccines in infants. 1, 2 Both vaccines are currently prequalifi ed by WHO and their introduction into national immunisation programmes has recently been recommended. 3 Rotaviruses are the leading cause of severe diarrhoeal disease and dehydration in infants and young children in high-income and low-income countries. 4 The virus is composed of three protein shells: an outer and an inner capsid, and an internal shell that encases the 11-segment double-stranded RNA genome. The inner capsid protein (VP6) allows the classifi cation into various groups, of which three groups (A-C) are known to include human rotaviruses. Nearly all of the commonly detected rotaviruses that aff ect human beings belong to group A. 5 The two structural outer capsid proteins, VP7 (G glycoprotein) and VP4 (P protein) defi ne the G and P serotypes of the virus, respectively. These major antigens are involved in virus neutralisation, and hence elicit the production of neutralising antibodies in the host and are thought to be important for vaccine development. These antigens allow the classifi cation of rotaviruses into a dual nomenclature system, depending on the G-P antigen combination (eg, G1P [8] or G2P [4] ).
The new rotavirus vaccines have proven effi cacy against some human rotavirus serotypes. Rotarix (GlaxoSmithKline Biologicals, Rixensart, Belgium) has been shown to be eff ective in the prevention of severe rotavirus gastroenteritis caused by G1P [8] , G3P [8] , G4P [8] , and G9P [8] .
1 Rotateq (Merck Co, Whitehouse Station, NJ, USA) has also proven to be eff ective in the prevention of hospital admissions and visits to the emergency department due to rotavirus strains G1, G3, G4, and G9. 2 Limited data also exists on effi cacy against G2 strains for both vaccines. To assess the expected impact of the vaccine introduction, knowledge of prevalent types is essential because an eff ective rotavirus vaccine should protect against prevailing serotypes in the community.
Recent estimates show that serotypes G1, G3, G4, and G9 account for 90% of all rotavirus infections in North America and Europe; however, these serotypes are responsible for less than 70% of cases in Africa. 6 Whereas P [8] and P [4] account for over 90% of P types circulating worldwide, the relative frequency of these two serotypes seems to be lower in Africa, where P [6] accounts for almost a third of all P types detected. 6 Countries in sub-Saharan Africa have a higher burden of diarrhoeal diseases and rotavirus-related deaths than the rest of the world. 7, 8 Although rotavirus is recognised as the most important causal agent implicated in severe diarrhoea in young children, summarised information available on its epidemiology in sub-Saharan Africa is limited to 19 studies from nine countries, mostly from eastern and southern Africa. 6, 9 We did two systematic reviews and two meta-analyses of the most recent published data on the burden of rotavirus disease in children aged under 5 years and on rotavirus serotypes circulating in countries in sub-Saharan Africa.
Review

Methods
Search strategy and selection criteria
We systematically searched PubMed/Medline, Cochrane Library, EmBase, LILACS, Academic Search Premier, Biological Abstracts, ISI Web of Science, and the African Index Medicus for articles published from January, 1990, to April, 2009, in English, French, Italian, Portuguese, or Spanish. We searched using the terms "rotavirus" and the name of the country. All countries in sub-Saharan Africa, as defi ned by the United Nations Educational, Scientifi c and Cultural Organisation were searched individually. 10 The list of publications obtained through this search was narrowed to studies thought to be relevant to disease burden and serotype circulation. Retrieved studies had to report either the proportion of rotavirus disease among children with acute diarrhoea, or G type, P type, or both characterisation of circulating rotavirus. Studies meeting both criteria were included in both reviews.
Studies based only on preterm infants or neonates, on asymptomatic or immunocompromised children, on children aged older than 5 years, or limited to outbreaks or to hospital-acquired infections were excluded. In addition, to quantify the burden of rotavirus disease, studies lasting less than 12 months or including fewer than 100 children were excluded.
Data abstraction and quality assessment
Two reviewers (ESP and FJL) independently extracted data from the detected studies. We gathered the following information from every study: country, study duration, defi nition of diarrhoea, inclusion criteria, representativeness and precision of the estimates, age-group, setting (community, outpatient department, or hospital based), number of samples tested, number of rotaviruspositive samples, typing method (if any), number of samples typed, and number of positive samples for each G and P type. Data were entered into a Microsoft Offi ce Excel database by the two reviewers (ESP and FJL). Diff erences in the data extracted were resolved by discussion with a third reviewer (RFG). We included cross-sectional and cohort studies. Studies reported from the same country were cross-referenced by location and time period to avoid data duplication.
Burden of rotavirus disease
We did a meta-analysis to obtain a point proportion of diarrhoea due to rotavirus for each country for which data was available and for all sub-Saharan Africa by agegroup. We used fi xed-eff ects models or the DerSimonianLaird random-eff ects methods, 11 depending on the heterogeneity of the studies, on the basis of Cochran's Q-test. The variances of the raw proportions given in each study were stabilised using a Freeman-Tukey-type arcsine square-root transformation (y=arcsine[√(r/ (n+1))]+arcsine[√(r/(n+1)/(n+1)]), with a variance of 1/(n+1), where n is the population size. 12 We calculated the I 2 statistic as a measure of the proportion of the overall variation in the proportion that was attributable to between-study heterogeneity. We also did a stratifi ed analysis to assess the weight of rotavirus infection on diarrhoeal disease according to age and setting of the study (community, outpatient department, or hospital based). If there was only one study in the country, we calculated the 95% CI by use of the exact test of ClopperPearson. 13 To calculate the mortality rate due to rotavirus, we followed the same methods published previously for obtaining global estimates of rotavirus deaths, 8, 14 and recommended by WHO. 15 By country and for all subSaharan Africa, we multiplied the population aged under 5 years by the mortality in this age-group to obtain the Review total number of deaths. 16 We then multiplied this number by the proportion of deaths due to diarrhoea (WHO country profi les) and by the combined proportion of diarrhoea hospital admissions due to rotavirus infection in children aged under 5 years (obtained through meta-analysis).
Circulating strains
The proportion of P genotypes and G serotypes or genotypes, non-typeable strains, and mixed infections were analysed independently. Again, the combined proportion of the diff erent genotypes or serotypes for each country and for all sub-Saharan Africa was calculated using fi xed-eff ects models or the DerSimonian-Laird random-eff ects method, depending on the heterogeneity of the studies, as explained above. All analyses were done with the statistical software R (version 2.7.2).
Results
Our search identifi ed 382 articles that were relevant to the objectives of this review. We excluded 335 articles according to the exclusion criteria. One article reported the results of 15 diff erent studies done in 12 countries in sub-Saharan Africa. 17 No additional studies were identifi ed through citations in articles. Figure 1 summarises the selection process and shows the number of articles included in both parts of the review. 35 articles (44 studies) were analysed for the burden of rotavirus disease and 31 articles (39 studies) for the circulating strains. Characteristics of the patient population, study design, setting, and severe diarrhoea defi nition diff ered among the included studies, and typing method varied widely (webappendix). The studies were done between 1984 and 2007, and the median starting date was 1997 (IQR 1991-99). Defi nition of acute diarrhoea was missing for 14 of 35 articles reporting data on burden of disease, and the selection criteria was absent in 22 of these studies. The age range used as inclusion criteria varied among studies, and the categories used to report the proportion of rotavirus diarrhoea by age-group also varied substantially. Samples were screened by EIA or ELISA in 35 studies, and with latex agglutination in four studies. 17, 18, 31, 46 Polyacrylamide gel electrophoresis was used in two studies, either combined with ELISA and electron microscopy, 30 or only with ELISA. 47 One study used both ELISA and electron microscopy, 25 another ELISA and latex agglutination, 61 and one used electropherotyping. 53 Rotavirus type-G characterisation was done in 35 studies, in fi ve studies by ELISA, 25, 47, 57, 59, 64 in 27 studies by reverse-transcription PCR (RT-PCR), and in three studies by both techniques.
17,38,58 Ptype genotyping was done in 33 studies, all of which used RT-PCR (webappendix).
Information was available on the proportion of rotavirus diarrhoea for 14 countries of 48 in the region (fi gure 2). The proportion of diarrhoea caused by rotavirus ranged between 0·6% for children aged under 2 years who were admitted to hospital in Mozambique 46 and 55·9% for children aged under 5 years who attended a hospital outpatient department in Nigeria. 53 In a stratifi ed analysis, by age and setting, meta-analysis showed that the highest proportion of diarrhoea attributable to rotavirus was in hospital-admitted children aged under 1 year (table 1) . The lowest proportion was observed in community-based studies that included Figure 3 shows a forest plot of the proportion of diarrhoea attributable to rotavirus by setting.
In sub-Saharan Africa, the global estimate of the annual rotavirus mortality rate was 243·3 (95% CI 187·6-301·7) deaths per 100 000 children aged under 5 years. This fi gure corresponds to 308 579 deaths per year due to rotavirus in this age-group. Mortality estimates could be made for seven countries from which the proportion of hospital admissions due to rotavirus diarrhoea in children aged under 5 years was available. The rotavirus mortality rate ranged from 6·2 (South Africa) to 301·0 (Nigeria) per 100 000 childrenyears (table 2). The median annual rotavirus mortality rate for the included countries was 193·3 (IQR 161·55-228·45) cases per 100 000 children younger than 5 years. The annual number of deaths due to rotavirus infection ranged from 323 in South Africa to 71 144 in Nigeria.
Information on the circulating rotavirus strains was available for 14 countries (fi gure 2). Summary proportions for each genotype are shown in tables 3 and 4. The most frequent G type detected was G1 (34·9%), followed by G2 (9·1%), and G3 (8·6%). G8 accounted for 3·3% of the infections, and G4 and G9 represented 1·9% and 2·6% each. The combined summary proportion (random-eff ects) for genotypes G1-G4 and G9 was 68·4% (95% CI 62·3-74·3; I²=94%; p<0·001). G12 strains were found in two studies, one done in Ghana (3·5%; 5 of 142) 27 and the other in Malawi (5·5%; 30 of 546). 45 7·8% of the samples contained more than one G-type strain, and in 15·4% the G type remained unknown (table 3) .
The most frequent P types detected were P [8] (35·5%) and P [6] (27·5%). P [4] accounted for 7·3% of the samples, and other P types for less than 0·5% each. Mixed genotypes accounted for 5·6% of the P-typed strains. Genotypes P [1] , P [2] , P [12] , and P [14] were detected in one study each: P [1] in Nigeria (0·9%; 1 of 110), 51 P [2] in Guinea Bissau (1·2%; 2 of 167), 34 P [12] in South Africa (2·6%; 6 of 227), 62 and P[14] also in South Africa (2·1%; 11 of 525). 17 Untyped P types accounted for 15·5% of the samples (table 4). The most common genotypes that presented with mixed infections were G2 and G8, and P [6] , P [4] , and P [8] .
Discussion
This study gathers the most recent published data on the burden of disease and the circulating strains of rotavirus in sub-Saharan Africa, and underscores the lack of information about rotavirus epidemiology in most of these countries. Rotavirus mortality rates vary widely within and between countries in sub-Saharan Africa from which information is available, as do the genotypes of circulating rotavirus strains. Our estimate that approximately 300 000 children aged under 5 years die of rotavirus infection in sub-Saharan Africa each year is higher than the most recent data provided by WHO (251 783 deaths per year).
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The diff erence between these estimates is mainly due to the assumed percentage of diarrhoeal deaths attributable to rotavirus. We applied the summary proportion of rotavirus infection in hospital-admitted children aged under 5 years who were suff ering from watery diarrhoea. However, the number of available studies to calculate this estimate was low, which means that imprecise estimates were used and substantial variations exist due to extreme values, as in the study by Mandomando and colleagues. 46 Therefore, even slight variations in the studies included can signifi cantly modify the global fi gures. Moreover, the reporting methods used are not standardised, which makes diffi cult the classifi cation of studies by setting.
The most accepted estimates of global rotavirus disease burden are based on the proportion of rotavirus cases seen at each health-care setting. 4 Good knowledge of the health-seeking behaviour of patients with diarrhoea is needed to extrapolate the observed proportion in diff erent settings to obtain the global burden of this disease. This information is missing in several regions of the world, including sub-Saharan Africa. The most accepted estimates of global rotavirus burden in low-income countries 8, 14 are based on the health-seeking behaviour seen in a Chilean cohort study, 72 but health-seeking behaviour is likely to vary between geographical regions, and the distribution of cases in the diff erent health-care settings varies substantially between Latin America and Africa. These limitations underscore the importance of not only gathering more information on rotavirus disease burden in sub-Saharan Africa, but ensuring that a Review standard method is used in data collection and reporting to produce robust estimates of public-health relevance. High heterogeneity was also seen in the reporting of circulating strains, and noteworthy geographic and time-dependent diff erences between countries were observed. RT-PCR was used by most of the studies, and although it is much more sensitive than serological methods, many strains remained untyped. Reasons for untyping could be because the correct primers were not used or because new or unusual genotypes were Review present. 6 Information on the circulating strains is important to enable assessment of the potential impact of rotavirus vaccination; to be eff ective, the vaccine must protect against the most prevalent serotypes. As other studies have shown, the most common genotypes (G1-G4, P [8] ) worldwide are underrepresented in countries in sub-Saharan Africa, and, by contrast, uncommon serotypes are more prevalent in this Review continent. 6, 9 The G8 serotype has been frequently detected in Africa since the mid-1990s, and represents the fourth most common genotype, whereas outside Africa it has seldom been detected. 6, 9 The two new licensed vaccines have proven their effi cacy mainly against the G1-G4 and G9, the most common serotypes in high-income countries, but our analysis shows that these serotypes only represent 68% of the circulating strains in sub-Saharan Africa. If the current vaccine formulation does not produce crossprotection against other genotypes more prevalent in countries in sub-Saharan Africa, their eff ectiveness could be reduced in this setting. Therefore, these genotypes may need to be included in future vaccines in order for them to be eff ective in these regions. 73 New P-G strains could emerge as the result of mixed rotavirus infections that account for up to 8% of the samples (summary proportion). When mixed infections with distinct rotavirus strains occur, the gene segments may reassort independently, producing reassortant strains, which is an important source of viral diversity. 74 Investigation of future rotavirus vaccines should consider the geographical variation in the distribution of genotypes. In India, a vaccine that potentially protects against local strains is under development. 6 The key limitation of this review is that the results may not be representative of all countries in subSaharan Africa. Data on disease burden and strain information was not available for many countries or did not meet the inclusion criteria for this analysis. Moreover, the included studies may not be representative of the country as a whole; none of the studies covered the whole country, and information on the representativeness of the sample was generally not given. Nevertheless, we tried to ensure that the most valid studies concerning the two objectives of this review were included through restrictive inclusion criteria. Another limitation is that mortality rate estimates are based on prevalence and not on incidence studies. Incidence studies are rare and are clearly needed for future research. Review WHO has recently recommended the inclusion of rotavirus vaccine worldwide, based principally on the additional preliminary results of vaccine effi cacy studies in two African countries (Malawi and South Africa). 75 Concerns about the safety and feasibility of the introduction of the rotavirus vaccine in low-income countries have been commented on elsewhere, 24, 76, 77 and include the previous poor responses of live oral vaccines observed in these settings, 78, 79 problems delivering the recommended number of doses, timing of fi rst dose administration, and the risk of intussusception if given to children older than recommended by manufacturers. 80 Documentation on the burden of disease and the circulating strains is essential to assess the eff ectiveness of the vaccines and the impact of their future introduction. To assess the burden of disease and the circulating strains, regional surveillance by standardised methods, which enable comparison between countries, should be either reinforced or developed. WHO strongly recommends sentinel surveillance before the introduction of the vaccines to monitor vaccine impact (although absence of surveillance should not stop vaccine introduction). 75 These sentinel surveillance systems should ideally measure mortality and morbidity, both hospital and community based, and the strains circulating, by RT-PCR based on new primers and standardised techniques. The African Regional Network-Rotavirus Surveillance Network is currently doing hospital-based surveillance of rotavirus disease in children aged under 5 years in 14 African countries with the support from WHO, 81 US Centers for Disease Control and Prevention, 82 and PATH's rotavirus vaccine programme. This critical eff ort should be expanded to other countries. After the implementation of the vaccines, adapted surveillance will ideally allow the detection of the impact of rotavirus vaccines on the burden of disease, possible adverse events, and the emergence of new strains as rotaviruses evolve.
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